AstraZeneca’s $2.4B acquisition of Fusion Pharmaceuticals marks milestone in cancer treatment
A McMaster University spin-out company, Fusion Pharmaceuticals, is being acquired by pharmaceutical giant AstraZeneca for $2.4 billion. Fusion, founded by McMaster professor John Valliant, develops radioconjugates for precision cancer treatment. By the second quarter of this year, the company will become a wholly-owned subsidiary…